ResearchSpace

Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort

Show simple item record

dc.contributor.author Kenmogne, VL
dc.contributor.author Takalani, AMT
dc.contributor.author Nweke, EE
dc.contributor.author Takundwa, Mutsa M
dc.contributor.author Fabian, June
dc.contributor.author Maher, Heather
dc.contributor.author Du Toit, Justin
dc.contributor.author Philip-Cherian, V
dc.contributor.author Fru, PF
dc.contributor.author Govindaraj, DBT
dc.date.accessioned 2023-12-11T08:13:11Z
dc.date.available 2023-12-11T08:13:11Z
dc.date.issued 2023-10
dc.identifier.citation Kenmogne, V., Takalani, A., Nweke, E., Takundwa, M.M., Fabian, J., Maher, H., Du Toit, J. & Philip-Cherian, V. et al. 2023. Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. <i>Hematology, Transfusion and Cell Therapy, 45(3).</i> http://hdl.handle.net/10204/13385 en_ZA
dc.identifier.issn 2531-1379
dc.identifier.issn 2531-1387
dc.identifier.uri https://doi.org/10.1016/j.htct.2023.09.053
dc.identifier.uri http://hdl.handle.net/10204/13385
dc.description.abstract Our objective is to develop a functional precision medicine platform designed to directly identify tailored drug regimens that target individual patient cancer cells and give benefit to the same donors by supporting clinical decision-making. We demonstrate our ex vivo drug sensitivity screening platform for precision medicine using Leukaemia and Multiple Myeloma samples from a South African patient cohort as proof of concept. en_US
dc.format Fulltext en_US
dc.language.iso en en_US
dc.relation.uri https://www.sciencedirect.com/science/article/pii/S2531137923002298 en_US
dc.source Hematology, Transfusion and Cell Therapy, 45(3) en_US
dc.subject Drug sensitivity en_US
dc.subject Ex vivo en_US
dc.subject Leukaemia en_US
dc.subject Myeloma en_US
dc.subject Patient cohort en_US
dc.title Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort en_US
dc.type Article en_US
dc.description.pages S32-S33 en_US
dc.description.cluster Next Generation Health en_US
dc.description.impactarea Synthetic Nanobiotech Biomachs en_US
dc.identifier.apacitation Kenmogne, V., Takalani, A., Nweke, E., Takundwa, M. M., Fabian, J., Maher, H., ... Govindaraj, D. (2023). Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. <i>Hematology, Transfusion and Cell Therapy, 45(3)</i>, http://hdl.handle.net/10204/13385 en_ZA
dc.identifier.chicagocitation Kenmogne, VL, AMT Takalani, EE Nweke, Mutsa M Takundwa, June Fabian, Heather Maher, Justin Du Toit, V Philip-Cherian, PF Fru, and DBT Govindaraj "Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort." <i>Hematology, Transfusion and Cell Therapy, 45(3)</i> (2023) http://hdl.handle.net/10204/13385 en_ZA
dc.identifier.vancouvercitation Kenmogne V, Takalani A, Nweke E, Takundwa MM, Fabian J, Maher H, et al. Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. Hematology, Transfusion and Cell Therapy, 45(3). 2023; http://hdl.handle.net/10204/13385. en_ZA
dc.identifier.ris TY - Article AU - Kenmogne, VL AU - Takalani, AMT AU - Nweke, EE AU - Takundwa, Mutsa M AU - Fabian, June AU - Maher, Heather AU - Du Toit, Justin AU - Philip-Cherian, V AU - Fru, PF AU - Govindaraj, DBT AB - Our objective is to develop a functional precision medicine platform designed to directly identify tailored drug regimens that target individual patient cancer cells and give benefit to the same donors by supporting clinical decision-making. We demonstrate our ex vivo drug sensitivity screening platform for precision medicine using Leukaemia and Multiple Myeloma samples from a South African patient cohort as proof of concept. DA - 2023-10 DB - ResearchSpace DP - CSIR J1 - Hematology, Transfusion and Cell Therapy, 45(3) KW - Drug sensitivity KW - Ex vivo KW - Leukaemia KW - Myeloma KW - Patient cohort LK - https://researchspace.csir.co.za PY - 2023 SM - 2531-1379 SM - 2531-1387 T1 - Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort TI - Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort UR - http://hdl.handle.net/10204/13385 ER - en_ZA
dc.identifier.worklist 27195 en_US


Files in this item

Thumbnail
Name: RS_27195_NGH_Esta ...
Size: 107.3Kb
Format: PDF
Description: Article
View/Open

This item appears in the following Collection(s)

Show simple item record